联合检测自发凋亡率及p27kip1在膀胱移行细胞癌中的意义

目的探讨自发凋亡率、p27kip1在人膀胱移行细胞癌中表达的临床意义。方法采用TUNEL法检测自发凋亡细胞,用S’P法检测p27kip1基因在50例膀胱移行细胞癌中的表达,分析各检测指标在上述标本中的表达及与膀胱移行细胞癌分级、临床分期间的关系。结果在膀胱移行细胞癌中,自发凋亡率AI均数为(3.0±1.5)%,p27kip1基因的阳性表达率为58.0%(29/50)。其二者的阳性表达均随膀胱癌分级、分期的升高而降低。p27kip1蛋白阳性组中AI均数显著高于p27kip1蛋白阴性组(P<0.05)。结论p27kip1蛋白和自发凋亡率与肿瘤的恶性程度和进展密切相关,联合检测p27kip1和自发凋亡率有助于更准确地解释和描述膀胱癌的生物学行为。     

p53基因与肝癌

p53肿瘤抑制基因突变与多数恶性肿瘤的发生发展有关,包括肝细胞癌(hepatocelluar carcinoma,HCC)在内的人类恶性肿瘤中至少有50%发生了p53基因改变。因此,以正常p53基因治疗肿瘤就成了研究热点,随着介入放射学(inter-ventional radiology)向纵深发展,经介入放射方法进行肝癌的基因治疗令人关注。本文介绍了p53基因的结构与功能,其与肝癌的病理联系以及在肝癌治疗中的应用。     

聚合酶链反应单链构象多态性检测乳腺癌中P53基因突变

应用聚合酶链反应单链构象多态性方法，对２４例原发性乳腺癌肿瘤组织基因组ＤＮＡ进行了分析，结果表明：其中７例存在Ｐ５３基因的突变，突变频率约为３０％。同时对其中１０例进行Ｓｏｕｔｅｒｎｂｌｏｔ分析，有２例在ｃｈｒ１７Ｐ上存在等位基因的缺失，而其另一等位基因上均存在基因突变。     

乳腺癌组织中Cyclin D1及p16蛋白表达的联合检测及其意义

目的:探讨乳腺癌中Cyclin D1及p16蛋白表达的相关性及其临床意义。方法:LSAB法检测多种乳腺组织中Cyclin D1及p16蛋白的表达情况,结合有关临床资料,分析Cyclin D1和p16蛋白表达异常与乳腺癌中重要的临床病理因素的关系。结果:62例乳腺癌组织中,Cyclin D1蛋白过度表达占48·4%,其表达与乳腺癌组织学分级呈明显正相关,且Cyclin D1蛋白过度表达更常见于ER、PR阳性的乳腺癌中。乳腺癌旁组织中Cyclin D1蛋白过度表达为20·0%,其他几种乳腺组织很少有CyclinD1蛋白的过度表达。p16蛋白仅在58·1%的乳腺癌组织中有表达,且p16的表达与组织学分级程度有负相关关系。正常乳腺组织中未见p16蛋白的异常。结论:乳腺癌组织中存在着Cyclin D1蛋白的过度表达及p16蛋白的异常,二者对乳腺癌组织的增殖分化有一定的影响。     

前列腺癌中E-钙粘素、p16及雌激素受体基因甲基化的检测及其临床意义

目的:研究前列腺病变中E-钙粘素、p16和雌激素受体(ER)基因启动子CpG岛甲基化状况及其与临床资料的关系,探讨基因过甲基化在前列腺癌(PCa)发生发展中的作用及其临床意义。方法:收集石蜡包埋前列腺全切术标本:良性前列腺增生(BPH)13例,高级别前列腺上皮内瘤(HGPIN)10例,有随访记录的PCa 20例。采用甲基化特异性PCR(MSP)技术对E-钙粘素、p16和ER基因CpG岛甲基化进行检测。结果:E-钙粘素、p16和ER基因过甲基化在PCa中的发生率分别为30%、25%和65%。非恶性病变(BPH和HGPIN)很少发生DNA过甲基化。结论:PCa的发生及进展与E-钙粘素、p16和ER基因过甲基化密切相关,检测甲基化状况对HGPIN与PCa的鉴别诊断可能有辅助作用。E-钙粘素和ER基因过甲基化可能提示预后差。     

Skp2、p27在急性白血病细胞中的表达及意义

采用免疫组化方法检测了Skp2及p27在32例急性白血病患者（AL组）及10例良性血液病患者（对照组）血细胞中的表达。结果AL组Skp2表达高于对照组，p27表达低于对照组，P均〈0．05。认为Skp2高表达与白血病的发生、发展密切相关，应用其抑制剂可为多靶位治疗白血病提供理论及技术基础。     

Identification of genes associated with ovarian cancer metastasis using microarray expression analysis

Although the transition from early- to advanced-stage ovarian cancer is a critical determinant of survival, little is known about the molecular underpinnings of ovarian metastasis. We hypothesize that microarray analysis of global gene expression patterns in primary ovarian cancer and metastatic omental implants can identify genes that underlie the metastatic process in epithelial ovarian cancer. We utilized Affymetrix U95Av2 microarrays to characterize the molecular alterations that underlie omental metastasis from 47 epithelial ovarian cancer samples collected from multiple sites in 20 patients undergoing primary surgical cytoreduction for advanced-stage (IIIC/IV) serous ovarian cancer. Fifty-six genes demonstrated differential expression between ovarian and omental samples (P < 0.01), and twenty of these 56 differentially expressed genes have previously been implicated in metastasis, cell motility, or cytoskeletal function. Ten of the 56 genes are involved in p53 gene pathways. A Bayesian statistical tree analysis was used to identify a 27-gene expression pattern that could accurately predict the site of tumor (ovary versus omentum). This predictive model was evaluated using an external data set. Nine of the 27 predictive genes have previously been shown to be involved in oncogenesis and/or metastasis, and 10/27 genes have been implicated in p53 pathways. Microarray findings were validated by real-time quantitative PCR. We conclude that gene expression patterns that distinguish omental metastasis from primary epithelial ovarian cancer can be identified and that many of the genes have functions that are biologically consistent with a role in oncogenesis, metastasis, and p53 gene networks.     

食管癌3p24等位基因LOH及其扩增产物克隆的研究

目的；研究3p24EAβMD位点与食管癌的关系。为寻找该位点附近可能存在的抑癌基因奠定基础。方法：采用PCR—RFLP法检测45例食管癌患者3p24位点杂合缺失情况。并对该片段进行克隆。结果：在22例食管癌信息个体中共检出9例杂合缺失。并通过序列分析可知变化为点突变。结论：3p24EAβMD较高的杂合缺失率显示该位点附近可能存在潜在的抑癌基因。     

The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers – a study of the National Cancer Institute of Canada Clinical Trials Group

A multicenter phase II trial was conducted to define the activity of letrozole in postmenopausal women with recurrent or advanced endometrial carcinoma, who had no more than one prior line of progestins and never had chemotherapy (except adjuvant). Archival paraffin-embedded tumor samples were retrieved to determine the expression level of estrogen (ER) and progesterone receptor (PgR), p53, HER-2, bcl-2 and PTEN protein, and phosphorylation status of protein kinase B (PKB/Akt). Thirty-two eligible patients were treated with letrozole at 2.5 mg daily continuously, of whom 10 (31%) had prior progestins. Of the 28 patients evaluated for response, one complete and two partial responses were noted; overall response was 9.4% (95% confidence interval 2-25%). Eleven patients had stable disease for a median duration of 6.7 months (range 3.7-19.3 months). Amongst 22 patients who had tumor blocks available, the proportion showing positive expression of the following markers includes: PgR (86%), ER (86%), PTEN (82%), phosphorylated PKB/Akt (59%), bcl-2 (45%), p53 (32%), and HER-2 (0%). None of these markers correlated with response to letrozole or disease progression. In conclusion, letrozole is well tolerated but has little overall activity in this cohort of women with endometrial cancer.